Status:
UNKNOWN
A Clinical Study on Levosimendan Improvement of Prognosis of ARDS Patients by Optimizing Pulmonary Hemodynamics
Lead Sponsor:
Shenzhen Second People's Hospital
Conditions:
ARDS, Human
Eligibility:
All Genders
Phase:
PHASE3
Brief Summary
The purpose of this study was to evaluate the curative effect of Levosimendan on ARDS patients through omni-directional and multi-angle objective quantitative indexes, and to study the responsiveness ...
Detailed Description
On the basis of the above research, the investigators speculate that Levosimendan can improve cardiac function, enhance diaphragm contractility and decrease pulmonary artery through this sensitizing e...
Eligibility Criteria
Inclusion
- Clinical diagnosis of ARDS; joined this study with informed consents
Exclusion
- neurological and muscle diseases; Chronic severe liver and kidney failure; advanced malignant tumor; Primary left ventricular insufficiency;
Key Trial Info
Start Date :
July 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 30 2022
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT04020003
Start Date
July 1 2019
End Date
August 30 2022
Last Update
July 15 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shenzhen Second People's Hospital
Shenzhen, Guangdong, China